Diagnostic Implications of Elevated Immunoglobulin Kappa Free Light Chain

Understanding Light-Chain MGUS

Light-chain MGUS is characterized by an abnormal κ/λ free light-chain ratio with increased concentration of the involved light chain (kappa in this case), according to the International Myeloma Society 1
The absence of a monoclonal peak of immunoglobulin heavy-chain on serum protein electrophoresis (SPEP) and immunofixation is a key feature of light-chain MGUS, as stated by the European Hematology Association 1
Bone marrow plasma cell percentage less than 10% is a diagnostic criterion for light-chain MGUS, as recommended by the American Society of Hematology 1, 2
The absence of end-organ damage attributable to the plasma cell proliferative disorder (no CRAB features: hypercalcemia, renal insufficiency, anemia, or bone lesions) is essential for the diagnosis of light-chain MGUS, according to the National Comprehensive Cancer Network 2

Serum immunofixation electrophoresis (SIFE) is required to confirm the absence of monoclonal heavy chains, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 3
Urine protein electrophoresis (UPEP) and urine immunofixation electrophoresis (UIFE) from a 24-hour collection are necessary to assess for Bence Jones proteinuria, according to the European Renal Association 3
Complete renal function assessment (serum creatinine, eGFR) is crucial, as renal impairment can affect free light chain levels and ratios, as stated by the National Kidney Foundation 3, 5

The risk of progression from light-chain MGUS to multiple myeloma or related disorders is approximately 1% per year, according to the International Myeloma Society 1, 2
Risk stratification should be performed based on the free light chain ratio, type of monoclonal protein, and concentration of monoclonal protein, as recommended by the American Society of Clinical Oncology 2

For low-risk MGUS, follow-up with SPEP at 6 months and, if stable, every 2-3 years thereafter, as recommended by the European Hematology Association 2
For intermediate and high-risk MGUS, follow-up in 6 months and then annually for life, including serum free light chain measurements, as stated by the National Comprehensive Cancer Network 2, 4

The same serum free light chain assay should be used throughout monitoring, as results between different assays are not mathematically convertible, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 3
Renal impairment can significantly affect free light chain levels and ratios, potentially leading to false positive results, as stated by the National Kidney Foundation 3, 5